
Is it withdrawal or relapse?
Key Takeaways
- Fluoxetine is not "self-tapering": withdrawal can occur despite its long half-life, and onset may be delayed weeks to months after discontinuation.
- New, unfamiliar, or unusually intense emotional symptoms accompanied by physical or sensory symptoms after discontinuation point toward withdrawal rather than relapse.
In this teaching case, an 18-year-old develops severe anxiety 2 months after stopping long-term fluoxetine because of hyperprolactinemia, raising the question of whether her symptoms reflect antidepressant withdrawal or relapse.
This composite teaching case integrates features drawn from multiple clinical experiences and the published literature.
An 18-year-old home from college for break presents with 4 months of amenorrhea but no galactorrhea. She has been taking fluoxetine 40 mg daily. Her prolactin level is 60 ng/mL, and thyroid function is normal. The radiologist interprets the MRI as possibly showing a pituitary adenoma, but the neurosurgeon is not convinced and recommends discontinuing fluoxetine before proceeding further. Believing that fluoxetine’s long half-life makes it “self-tapering” and unlikely to cause withdrawal, you stop the medication.
1. Can fluoxetine increase the prolactin level? Yes. In adolescents, selective serotonin reuptake inhibitors, including fluoxetine, have been associated with hyperprolactinemia and related symptoms such as amenorrhea and galactorrhea.1
2. Is fluoxetine self-tapering? No. Fluoxetine is not self-tapering. Pediatric reviews identify withdrawal symptoms after fluoxetine discontinuation, although the frequency and severity of fluoxetine-specific withdrawal remain poorly characterized.2,3 Withdrawal is not caused simply by the drug leaving the body. Declining exposure reduces the drug’s effects on receptors and other nervous system processes, disrupting neuroadaptations that developed during treatment.3-5 Adult evidence documents clinically important and protracted fluoxetine withdrawal; in one series of 69 reports of protracted withdrawal, fluoxetine was implicated in approximately 10% of cases.6 Fluoxetine was also among the 15 antidepressants evaluated in a World Health Organization pharmacovigilance analysis of withdrawal reports, showing that withdrawal reports occur despite its long half-life.7
3. When should fluoxetine be tapered, and when may abrupt discontinuation be necessary? Antidepressants should generally be tapered to reduce withdrawal risk.3,8 Pediatric literature supports gradual, symptom-guided dose reduction but does not establish an optimal tapering approach.2,3 Emerging adult evidence supports hyperbolic tapering, in which reductions become progressively smaller as the dose decreases and the pace is adjusted to symptoms.4,8,9 UK adult guidance indicates that tapering after long-term use may require months or longer.8 More rapid reduction or abrupt discontinuation may be necessary when continued exposure poses an urgent or serious medical risk; clinicians should balance that risk against withdrawal risk and monitor closely.3,8,10
Two months later, she develops her first panic attacks. Her anxiety is now severe, with early-morning awakening and intense dread despite no identifiable stressors. She has begun missing substantial amounts of school; summer vacation is approaching.
1. Does the worsening anxiety indicate relapse and the need to restart or add a new medication?
Do not assume relapse simply because anxiety or other emotional symptoms worsen after dose reduction or discontinuation. In a prospective adult study, emotional symptoms worsened after dose reductions along with physical withdrawal symptoms and improved when the dose was held, supporting their interpretation as withdrawal rather than relapse.11 Withdrawal in children and adolescents can also include emotional symptoms; a pediatric systematic review reported anxiety or worry and inner tension in 44% of participants and depression in 10%.2
2. What other information would help you distinguish relapse from withdrawal?
- Find out whether the emotional symptoms are worse now than the original symptoms were. Adult guidance indicates that emotional symptoms are more likely to reflect withdrawal when they are new, unusually intense, or different from the patient’s original condition.5,8
- Find out how long she has been taking fluoxetine.
Adult evidence indicates that longer treatment duration is associated with greater withdrawal risk. In a primary care survey, use for more than 24 months was associated with substantially higher odds of withdrawal syndrome, severe withdrawal effects, longer-lasting symptoms, and inability to stop compared with use for less than 6 months.12 Pediatric evidence is insufficient to determine whether the same relationship applies to children and adolescents; however, pediatric clinicians should remain alert to this possibility when assessing withdrawal after long-term treatment.
- Find out whether she has been poorly adherent to the medication.
Irregular adherence can provoke withdrawal symptoms because missed doses cause abrupt reductions in drug exposure. This is more likely with antidepressants that have shorter half-lives; after an occasional missed dose of fluoxetine, symptoms may be delayed or less immediate because fluoxetine and norfluoxetine are eliminated slowly.3,5,8
- Find out whether she has had physical or sensory symptoms that she may not have volunteered, including dizziness, nausea, palpitations, sound sensitivity, or electric shock sensations.
Her mother describes the anxiety as strange: nothing triggers it, and it is much worse than the condition for which fluoxetine was originally prescribed. You learn that she has taken fluoxetine for 6 years; treatment began at age 12, and the need for continued treatment was not systematically reassessed during the transition from adolescence to young adulthood. Her mother also reports periods of missed doses, especially since she started college. When you ask specifically about physical symptoms—including sleep problems, nausea, dizziness, photophobia, tinnitus, sound sensitivity, chest pain, palpitations, and brain zaps—she reports sleep problems, sound sensitivity, and palpitations.
Could withdrawal symptoms first emerge 2 months after stopping fluoxetine? Yes. Fluoxetine and norfluoxetine are eliminated slowly, so withdrawal may be delayed. In pediatric discontinuation trials, events classified as relapse occurred a mean of 71.2 days after discontinuation in one study, while another reported median times of 8 weeks to clinical deterioration and 14 weeks to full relapse.13,14 Stimpfl and colleagues3 later noted that withdrawal-emergent symptoms were more common after switching to placebo than with continued fluoxetine, and Wang and Cosci2 identified serious delayed events as possible persistent withdrawal outcomes. Because these trials did not assess withdrawal as an alternative explanation, some delayed withdrawal reactions may have been misclassified as relapse. Adult reports of onset as late as 13 weeks further support this possibility.5,15
You remain uncertain whether the symptoms represent withdrawal or relapse. Because sleep disturbance and anxiety can occur in either condition, you review the pattern of symptoms, their relationship to medication changes, and their course over time using the clinical features summarized below.
The table highlights several features that increase concern for withdrawal in this case: symptoms that are unfamiliar and more severe than the original condition, long-term treatment, irregular adherence, new physical and sensory symptoms, and delayed onset after discontinuing a medication with a long half-life.
Clinical feature
Withdrawal
Relapse
Relationship to medication change
Symptoms emerge after dose reduction, missed doses, or discontinuation; onset may be delayed with a drug with a long half-life, such as fluoxetine.
Symptoms are not necessarily closely linked to a medication reduction or discontinuation.
Symptom pattern
Psychological symptoms may occur with physical or sensory symptoms, such as dizziness, nausea, palpitations, sound sensitivity, or electric shock sensations.
Symptoms more often resemble the original disorder without prominent new physical or sensory symptoms.
Quality of psychological symptoms
Emotional symptoms may feel unfamiliar, unusually intense, or qualitatively different from the original condition.
Symptoms more often resemble the previous illness in quality and pattern.
Course over time
Symptoms may follow a wavelike pattern of onset, peak, partial resolution, and temporary recurrence while the overall trajectory improves.
Symptoms more often persist in a pattern consistent with recurrence of the underlying condition and are more constant over time.
Response to reinstatement
Symptoms may improve promptly after reinstatement, although decisions about reinstatement require individualized clinical judgment.
Improvement after restarting treatment is generally expected over the usual therapeutic time course rather than within days.
Response to pausing the taper when uncertain
If symptoms emerge during tapering, holding the current dose until symptoms resolve or become tolerable may support withdrawal and may indicate that subsequent reductions should be smaller or more widely spaced.
Recurrence of the underlying condition would not necessarily be expected to subside simply because the taper is paused.
Clinical features are synthesized from adult evidence on distinguishing antidepressant withdrawal from relapse.5 Pausing the taper and monitoring symptoms is consistent with symptom-guided tapering recommendations.4,8,9 Pediatric evidence remains limited; improvement during a pause is supportive rather than diagnostic, and no single feature confirms withdrawal or relapse.
Despite the features suggesting withdrawal, you remain influenced by the prior misconception that fluoxetine is effectively self-tapering, the erroneous assumption that worsening anxiety necessarily indicates relapse, and the parents’ urgent wish for treatment. You therefore discount the atypical features and recommend changing to a different medication.
The patient declines because she is worried about the elevated prolactin level and does not want to take another medication. Her parents, frightened by how ill she appears and eager to relieve her suffering, urge her to reconsider. One month after fluoxetine discontinuation, her prolactin level has decreased substantially but remains mildly elevated.
What are the adverse outcomes of having an elevated prolactin level?
Sustained hyperprolactinemia in an adolescent can suppress the hypothalamic-pituitary-gonadal axis, causing amenorrhea, galactorrhea, and hypogonadism. Prolonged sex hormone suppression during adolescence may impair bone mineral accrual and contribute to low bone mineral density. The underlying cause, including possible medication exposure, should therefore be evaluated.10,16
You have not heard from the family. Concerned that an untreated relapse may be worsening, you call. Her mother tells you that the patient never restarted fluoxetine and is much better. Recovery was not linear: symptoms temporarily returned after periods of improvement, but the overall trajectory remained upward. By 6 months, her prolactin level had normalized, regular menses had resumed, and she had improved without reinstatement. The family was relieved that no surgical intervention was recommended.
What looked like relapse was most consistent with withdrawal. Symptoms began after discontinuation; the emotional symptoms were unfamiliar and markedly more severe than those associated with her original condition; physical symptoms were present; treatment had been long-term; and symptoms fluctuated while the overall trajectory improved without reinstatement. Misdiagnosing these symptoms as relapse would have led to unnecessary medication treatment and additional exposure to adverse effects.5,11
References
Adıgüzel S, Hamoda HM. SSRI-induced galactorrhea in adolescents. J Child Adolesc Psychopharmacol. 2026;36(4):240-243. doi:10.1177/10445463261436376
Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Ther Adv Psychopharmacol. 2025;15:1-15. doi:10.1177/20451253251404780
Stimpfl JN, Walkup JT, Robb AS, et al. Deprescribing antidepressants in children and adolescents: a systematic review of discontinuation approaches, cross-titration, and withdrawal symptoms. J Child Adolesc Psychopharmacol. 2025;35(1):3-22. doi:10.1089/cap.2024.0099
Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546. doi:10.1016/S2215-0366(19)30032-X
Horowitz MA, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Adv. 2022;28(5):297-311. doi:10.1192/bja.2021.62
Hengartner MP, Schulthess L, Sørensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol. 2020;10:2045125320980573. doi:10.1177/2045125320980573
Quilichini JB, Revet A, Garcia P, et al. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: a real-world study using the WHO pharmacovigilance database. J Affect Disord. 2022;297:189-193. doi:10.1016/j.jad.2021.10.041
Stopping antidepressants. Royal College of Psychiatrists. Published March 2024. Accessed October 19, 2026.
https://www.rcpsych.ac.uk/mental-health/treatments-and-wellbeing/stopping-antidepressants Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Ther Adv Psychopharmacol. 2021;11:2045125321991274. doi:10.1177/2045125321991274
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi:10.1210/jc.2010-1692
Hengartner MP, Rennwald A, Senn O, Neuner-Jehle S, Horowitz MA. Acute affective symptoms during antidepressant tapering indicate withdrawal reactions rather than relapse: results from a prospective longitudinal cohort study. Psychother Psychosom. Published online August 13, 2026. doi:10.1159/pps/aemag002
Horowitz MA, Buckman JEJ, Saunders R, Aguirre E, Davies J, Moncrieff J. Antidepressants withdrawal effects and duration of use: a survey of patients enrolled in primary care psychotherapy services. Psychiatry Res. 2025;350:116497. doi:10.1016/j.psychres.2025.116497
Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1397-1405. doi:10.1097/01.chi.0000140453.89323.57
Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry. 2008;165(4):459-467. doi:10.1176/appi.ajp.2007.07091453
Stockmann T, Odegbaro D, Timimi S, Moncrieff J. SSRI and SNRI withdrawal symptoms reported on an internet forum. Int J Risk Saf Med. 2018;29(3-4):175-180. doi:10.3233/JRS-180018
Eren E, Yapıcı Ş, Papatya Çakır ED, Aytekin Ceylan L, Sağlam H, Tarım Ö. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol. 2011;3(2):65-69. doi:10.4274/jcrpe.v3i2.14
Related to this article








